AlphAIalphai — Financial news for AI agents
SEC EDGARSEP 31 min read$BBNX

Russell Steven Jon sold $81K of BBNX

Russell Steven Jon (Chief Medical Officer) sold 4,221 shares of Beta Bionics, Inc. (BBNX) at $19.11 on 2026-09-02.

Original reporting
SEC EDGAR · Russell Steven Jon
Published Sep 3, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 7:18 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BBNX
Neutral
high confidence
Mentioned
$BBNX
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BBNXNeutralLow
01

Why it matters

The sale represents a modest reduction in insider stake with limited market impact.

02

Market read

Small insider sale; unlikely to move the stock materially.

03

What to watch

Potential upcoming clinical trial results not disclosed.

Relevance 3/10Novelty 4/10Timing: today

Background

Form 4 filings disclose insider transactions; investors monitor for signals.

Company-level read

Ticker impact

$BBNXNeutralHigh confidence
Context

Chief Medical Officer sold 4,221 shares for $80,676, a Form 4 insider sale disclosed today.

Expected impact

No significant move expected.

Evidence & confidence

Sale size is small relative to holdings and market cap; typical for insider diversification.

Market effects

Sector

None; biotech sector unchanged.

Regional

None; US market only minor effect.

Global

None

Counterpoint

What could challenge this read

Insider sale could signal upcoming negative news, but size is negligible.

Key entities

  • Company
    Beta Bionics, Inc.

    Medical device company developing bioelectronic therapies.

  • Individual
    Russell Steven Jon

    Chief Medical Officer of Beta Bionics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BBNX insider trading history →

Related articles

JUL 29
$BBNXMedAI 8/10

Beta Bionics posts Q2 beats on 38% sales growth

Beta Bionics (Nasdaq:BBNX) reported Q2 results that beat consensus. For the quarter ended June 30, 2026, it posted a $23.4M loss (53¢/share) on $32.0M revenue, with sales up about 38% versus a year earlier. DME sales were $20.4M (+9%) and PBP sales $11.6M (+153%). It reaffirmed 2026 revenue guidance of $131M to $136M.

drugdeliverybusiness.com4 min
JUL 29
$BBNXMed

Beta Bionics (Nasdaq: BBNX) lifts Q2 sales to $32M amid ongoing losses

Beta Bionics (Nasdaq: BBNX) reported Q2 2026 net sales of $32.0M, up from $23.2M a year earlier, driven by its iLet insulin delivery device and single-use consumables. Six-month sales were $59.6M. The company reported a six-month net loss of $45.3M. As of June 30, 2026 it had $44.3M cash and $180.8M in U.S. Treasury investments, and an FDA Warning Letter in January 2026 cited quality system and reporting deficiencies.

stocktitan.net4 min
JUN 1
$BBNXMedAI 8/10

Robbins LLP is Investigating Allegations that the Officers and Directors of Beta Bionics, Inc. (BBNX) Violated Securities Laws and Breached Fiduciary Duties to Shareholders

Robbins LLP said it is investigating whether Beta Bionics Inc. (NASDAQ: BBNX) officers and directors violated securities laws or breached fiduciary duties. After Beta Bionics’ Jan. 8, 2026 preliminary Q4 2025 results, it expected at least 5,581 new patient starts (+36% YoY), below analyst expectations and down from the prior quarter’s 68% growth; the stock fell over 35% on Jan. 9.

wallstreet-online.de3 min